The global PD-1 inhibitor drugs market was valued at US$ 41.4 billion in 2024 and is projected to surpass US$ 201.5 billion by 2035, expanding at a remarkable CAGR of 15.5% from 2025 to 2035. The market growth is primarily driven by the rising global burden of cancer, increasing adoption of immunotherapy, and expanding clinical applications of PD-1 inhibitors across multiple oncology...